<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Tzu Chi Med J</journal-id>
<journal-id journal-id-type="iso-abbrev">Ci Ji Yi Xue Za Zhi</journal-id>
<journal-id journal-id-type="publisher-id">TCMJ</journal-id>
<journal-title-group>
<journal-title>Tzu-Chi Medical Journal</journal-title>
</journal-title-group>
<issn pub-type="ppub">1016-3190</issn>
<issn pub-type="epub">2223-8956</issn>
<publisher>
<publisher-name>Wolters Kluwer - Medknow</publisher-name>
<publisher-loc>India</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32269945</article-id>
<article-id pub-id-type="pmc">7137370</article-id>
<article-id pub-id-type="publisher-id">TCMJ-32-137</article-id>
<article-id pub-id-type="doi">10.4103/tcmj.tcmj_103_19</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Clinical characteristics and epilepsy in genomic imprinting disorders: Angelman syndrome and Prader–Willi syndrome</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Tzong-Shi</given-names>
</name>
<xref ref-type="aff" rid="aff1">a</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tsai</surname>
<given-names>Wen-Hsin</given-names>
</name>
<xref ref-type="aff" rid="aff2">b</xref>
<xref ref-type="aff" rid="aff3">c</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tsai</surname>
<given-names>Li-Ping</given-names>
</name>
<xref ref-type="aff" rid="aff2">b</xref>
<xref ref-type="aff" rid="aff3">c</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wong</surname>
<given-names>Shi-Bing</given-names>
</name>
<xref ref-type="aff" rid="aff2">b</xref>
<xref ref-type="aff" rid="aff3">c</xref>
<xref ref-type="corresp" rid="cor1">*</xref>
</contrib>
</contrib-group>
<aff id="aff1"><label>a</label>Department of Psychiatry, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei, Taiwan</aff>
<aff id="aff2"><label>b</label>Department of Pediatrics, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei, Taiwan</aff>
<aff id="aff3"><label>c</label>School of Medicine, Tzu Chi University, Hualien, Taiwan</aff>
<author-notes>
<corresp id="cor1"><label>*</label><bold><italic>Address for correspondence: </italic></bold> Dr. Shi-Bing Wong, Department of Pediatrics, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, 289, Jianguo Road, Xindian District, New Taipei, Taiwan. E-mail: <email xlink:href="wongshibing@tzuchi.com.tw">wongshibing@tzuchi.com.tw</email></corresp>
</author-notes>
<pub-date pub-type="collection">
<season>Apr-Jun</season>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>31</day>
<month>10</month>
<year>2019</year>
</pub-date>
<volume>32</volume>
<issue>2</issue>
<fpage>137</fpage>
<lpage>144</lpage>
<history>
<date date-type="received">
<day>02</day>
<month>5</month>
<year>2019</year>
</date>
<date date-type="rev-recd">
<day>03</day>
<month>6</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>03</day>
<month>9</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright: © 2019 Tzu Chi Medical Journal</copyright-statement>
<copyright-year>2019</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/4.0">
<license-p>This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.</license-p>
</license>
</permissions>
<abstract>
<p>Angelman syndrome (AS) and Prader–Willi syndrome (PWS) are considered sister imprinting disorders. Although both AS and PWS congenital neurodevelopmental disorders have chromosome 15q11.3-q13 dysfunction, their molecular mechanisms differ owing to genomic imprinting, which results in different parent-of-the-origin gene expressions. Recently, several randomized controlled trials have been proceeded to treat specific symptoms of AS and PWS. Due to the advance of clinical management, early diagnosis for patients with AS and PWS is important. PWS is induced by multiple paternal gene dysfunctions, including those in MKRN3, MAGEL2, NDN, SNURF-SNPRPN, NPAP1, and a cluster of small nucleolar RNA genes. PWS patients exhibit characteristic facial features, endocrinological, and behavioral phenotypes, including short and obese figures, hyperphagia, growth hormone deficiency, hypogonadism, autism, or obsessive– compulsive-like behaviors. In addition, hypotonia, poor feeding, failure to thrive, and typical facial features are major factors for early diagnosis of PWS. For PWS patients, epilepsy is not common and easy to treat. Conversely, AS is a single-gene disorder induced by ubiquitin-protein ligase E3A dysfunction, which only expresses from a maternal allele. AS patients develop epilepsy in their early lives and their seizures are difficult to control. The distinctive gait pattern, excessive laughter, and characteristic electroencephalography features, which contain anterior-dominated, high-voltage triphasic delta waves intermixed with epileptic spikes, result in early suspicion of AS. Often, polytherapy, including the combination of valproate, levetiracetam, lamotrigine, and benzodiazepines, is required for controlling seizures of AS patients. Notably, carbamazepine, oxcarbazepine, and vigabatrin should be avoided, since these may induce nonconvulsive status epilepticus. AS and PWS presented with distinct clinical manifestations according to specific molecular defects due to genomic imprinting. Early diagnosis and teamwork intervention, including geneticists, neurologists, rehabilitation physicians, and pulmonologists, are important. Epilepsy is common in patients with AS, and after proper treatment, seizures could be effectively controlled in late childhood or early adulthood for both AS and PWS patients.</p>
</abstract>
<kwd-group>
<title>K<sc>EYWORDS</sc>:</title>
<kwd>
<italic>Angelman syndrome</italic>
</kwd>
<kwd>
<italic>Epilepsy</italic>
</kwd>
<kwd>
<italic>Genomic imprinting</italic>
</kwd>
<kwd>
<italic>Prader–Willi syndrome</italic>
</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-1" sec-type="intro">
<title>I<sc>NTRODUCTION</sc></title>
<p>Both Angelman syndrome (AS) and Prader–Willi syndrome (PWS) are associated with chromosome 15q11.2-q13 dysfunction and are considered sister imprinting disorders [<xref ref-type="bibr" rid="ref1">1</xref>]. Although both congenital disorders map to the same chromosome locus, their molecular mechanisms, and clinical phenotypes differ because of genomic imprinting. The clinical phenotypes of AS are more restricted than those of PWS in neurological dysfunction, including cognitive impairment, seizures, and ataxia, which are also present in PWS patients with less severity. Conversely, PWS patients develop multiple behavioral and endocrinological disorders, including autistic and obsessive–compulsive symptoms, growth hormone deficiency, and hypogonadism [<xref ref-type="bibr" rid="ref1">1</xref><xref ref-type="bibr" rid="ref2">2</xref>]. The seizure is a cardinal manifestation of AS with characteristic electroencephalography (EEG) pattern, which could aid in the early diagnosis [<xref ref-type="bibr" rid="ref3">3</xref>]. Instead, the seizure types and EEG patterns of PWS patients are more assorted [<xref ref-type="bibr" rid="ref4">4</xref><xref ref-type="bibr" rid="ref5">5</xref>]. Recently, several randomized controlled trials have been proceeded to treat specific symptoms of AS and PWS, such as AZP-531 for hyperphagia [<xref ref-type="bibr" rid="ref6">6</xref>], oxytocin (OXT) for behavior problems of PWS [<xref ref-type="bibr" rid="ref7">7</xref>], and gaboxadol for the neurodevelopment of AS [<xref ref-type="bibr" rid="ref8">8</xref>]. Due to the advance of clinical management, early diagnosis for patients with AS and PWS is important. Therefore, the present review aimed to introduce the clinical phenotypes, molecular mechanisms, seizure semiology, EEG patterns, and treatments of AS and PWS.</p>
</sec>
<sec id="sec1-2">
<title><sc>CLINICAL FEATURES OF ANGELMAN SYNDROME AND PRADER</sc>–<sc>WILLI SYNDROME</sc></title>
<p>AS is a severe neurodevelopmental disorder induced by the loss of function of the ubiquitin-protein ligase E3A (<italic>UBE3A</italic>) gene, which is expressed from the maternal chromosome 15 only, and the estimated incidence is 1/12,000–20,000 [<xref ref-type="bibr" rid="ref9">9</xref><xref ref-type="bibr" rid="ref10">10</xref><xref ref-type="bibr" rid="ref11">11</xref>]. Typically, AS patients present with psychomotor delay since the age of 6 months, and this disorder is associated with feeding difficulties and muscular hypotonia [<xref ref-type="bibr" rid="ref12">12</xref>]. Most children with AS walk independently after 3–4 years of age with a distinguishing gait pattern – a puppet-like, jerky quality with an out-toed, wide-based stance with pronated ankles [<xref ref-type="bibr" rid="ref13">13</xref>]. Moreover, AS patients display a specific behavioral phenotype as excessive laughter and happy grimacing, which are introduced by social interaction and often associated with a protruding tongue [<xref ref-type="bibr" rid="ref14">14</xref>]. Usually, microcephaly and seizure develop in the 1<sup>st</sup> 3 years of life [<xref ref-type="bibr" rid="ref3">3</xref><xref ref-type="bibr" rid="ref12">12</xref>]. Seizures and declined physical mobility is the leading lifelong cardinal problems for AS patients. Obesity has been noted in some patients after teenage but is not a common finding [<xref ref-type="bibr" rid="ref15">15</xref>]. AS-related mortality exhibits a bimodal distribution, with some early deaths attributable to the complications of severe seizures or accidental events. Unlike PWS patients, endocrinopathy and sudden death are uncommon in AS patients. The lifespan of AS patients is considerably long beyond childhood [<xref ref-type="bibr" rid="ref16">16</xref>].</p>
<p>Unlike AS in which the symptoms are mostly restricted to the neurological system, PWS is a multisystem disorder caused by the loss of function of multiple genes from paternal chromosome 15q11-13. Affected infants present with marked hypotonia since birth, which results in feeding difficulties and failure to thrive. The characteristic facial features, including narrow bifrontal diameter, almond-shaped palpebral fissures, narrow nasal bridge, and thin upper vermillion, may be observed since birth [<xref ref-type="bibr" rid="ref2">2</xref>]. Moreover, neonatal hypotonia, feeding difficulties, and typical facial appearance are major factors leading to an early diagnosis of PWS. Majority of the patients exhibit delayed motor and language milestones, as well as intellectual disability (mean intelligence quotient, 60–70). Since toddler and childhood, excessive appetite develops, and patients gradually become obese [<xref ref-type="bibr" rid="ref17">17</xref>]. Hypothalamic dysfunction is another cardinal symptom of PWS, which is manifested as temperature dysregulation, enhanced pain tolerance, lack of satiety that, perhaps, induces food-seeking behavior, and sleep-disordered breathing, including central and obstructive sleep apnea [<xref ref-type="bibr" rid="ref18">18</xref>]. Besides, hypothalamic dysfunction results in central hypothyroidism, central adrenal insufficiency, growth hormone deficiency, and hypogonadotropic hypogonadism [<xref ref-type="bibr" rid="ref2">2</xref><xref ref-type="bibr" rid="ref18">18</xref>]. PWS patients exhibit a characteristic behavioral phenotype, including temper tantrums, stubbornness, controlling and manipulative behavior, compulsivity, and difficulty in changing routines, which even fulfill the criteria for the diagnosis of autistic spectrum disorder (ASD) [<xref ref-type="bibr" rid="ref2">2</xref>]. However, autistic and compulsive behaviors are rare in AS patients. Veltman <italic>et al.</italic> reported that 38 out of 150 (25.3%) PWS patients and 2 out of 104 (1.9%) AS patients had ASD as a morbidity [<xref ref-type="bibr" rid="ref19">19</xref>]. The neurodevelopmental disabilities of the PWS patients, such as mental retardation, autistic features, and emotional symptoms, persist into adulthood and pose marked challenges and burdens for their caregivers [<xref ref-type="bibr" rid="ref20">20</xref><xref ref-type="bibr" rid="ref21">21</xref><xref ref-type="bibr" rid="ref22">22</xref><xref ref-type="bibr" rid="ref23">23</xref>]. The estimated incidence of PWS is 1/10,000–30,000. The PWS-related mortality rate is higher than that in controls with intellectual disability. A population study estimated the PWS-related mortality rate at 3% per year [<xref ref-type="bibr" rid="ref24">24</xref>]; however, with enhanced supportive care and proper diet to control body weight, PWS patients may live a full life.</p>
</sec>
<sec id="sec1-3">
<title>G<sc>ENETICS FOR ANGELMAN SYNDROME AND PRADER–WILLI SYNDROME</sc></title>
<p>AS and PWS are caused by the same chromosome dysfunction, mostly caused by deletion, on 15q11.2-q13; this region contains several genes and has a typical parent-of-the-origin expression, termed genomic imprinting, which implies monoallelic and parent-of-origin-dependent expression of a subset of genes [<xref ref-type="fig" rid="F1">Figure 1</xref>]. The mechanism of genomic imprinting involves differential epigenetic markings of the alleles, primarily from parental allele-specific DNA methylation and chromatin modification during gametogenesis in the male and female germline [<xref ref-type="bibr" rid="ref25">25</xref><xref ref-type="bibr" rid="ref26">26</xref>]. Thus, the loss of function of the active allele cannot be compensated by another allele, making the imprinted genes more vulnerable. Four different mechanisms cause imprinted gene dysfunction, including gene mutation, chromosome deletion or duplication, uniparental disomy (UPD), and imprinting defect [<xref ref-type="bibr" rid="ref27">27</xref>]. UPD is caused by meiotic and mitotic nondysfunction events and makes both copies of a chromosome pair from the same parent. The imprinting defect makes wrong parental allele methylation, and further disarrays the imprinted gene function. AS and PWS are typical examples of imprinting disorders, for which the parental origin of the affected chromosome 15 would be the determining factor for clinical phenotypes [<xref ref-type="bibr" rid="ref28">28</xref>].</p>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<p>Genes in chromosome 15q11.2-q13. This chromosomal region begins from four non-imprinted genes (blue eclipses) and follows by Prader–Willi syndrome region, including five paternal-expressed functional genes (<italic>MKRN3, MAGEL2, NDN, NPAP1, SNURF-SNRPN</italic>) and a family of paternal-expressed snoRNA genes (orange squares). Those five functional genes in maternal allele are methylated and nonfunctional. Prader–Willi syndrom/Angelman syndrome imprinting center is included in this region. The Angelman syndrome region includes two maternal-expressed genes, <italic>UBE3A and ATP10A</italic> (red diamonds), followed by five non-imprinted genes, including <italic>GABRB3, GABRA5, GABRG3, OCA2,</italic> and <italic>HERC2</italic> (blue eclipses). BP: Breaking point, IC: Imprinting center, snoRNA: Small nucleolar RNA, <italic>SNHG14</italic>: Small nucleolar RNA host gene 14</p>
</caption>
<graphic xlink:href="TCMJ-32-137-g001"></graphic>
</fig>
<p>AS is a single-gene disorder caused by the loss of function of maternally expressed gene <italic>UBE3A</italic> in neuronal cells [<xref ref-type="bibr" rid="ref9">9</xref>]. The <italic>UBE3A</italic> gene comprises 16 exons and encodes E6-AP, an E3 ubiquitin ligase [<xref ref-type="bibr" rid="ref11">11</xref>]. Unlike the PWS gene expression, which is regulated by DNA methylation, the imprinted expression of <italic>UBE3A</italic> is regulated by small RNA host gene 14 (small nucleolar RNA host gene 14 [<italic>SNHG14</italic>]; previously termed <italic>UBE3A-ATS</italic>), a noncoding antisense transcript that is initiated at the <italic>SNRPN</italic> promoter [<xref ref-type="bibr" rid="ref29">29</xref>]. In neuronal cells, <italic>SNHG14</italic> transcription extends to the <italic>UBE3A</italic> gene and interferes with UBE3A expression on the paternal chromosome, and only maternal <italic>UBE3A</italic> is functional. However, <italic>UBE3A</italic> is biallelically expressed in nonneuronal cells [<xref ref-type="bibr" rid="ref30">30</xref>]. E6-AP transfers ubiquitin from an E2 ubiquitin-conjugating enzyme to its protein substrates, which is called ubiquitylation, and processes the protein substrates into specific functions, including membrane transport, transcriptional regulation, or degradation [<xref ref-type="bibr" rid="ref16">16</xref>]. From <italic>Drosophila</italic> and mice experiments, several protein levels are altered by E6-AP knockout or overexpression, such as ECT2, p53, p27, HR23A, Arc, and ephexin-5; p27 and p52 are involved in regulating neuronal cell proliferation and survival, whereas ephexin-5 and Arc are involved in synapse formation and remodeling [<xref ref-type="bibr" rid="ref16">16</xref>]. Thus, the clinical phenotypes of AS are primarily constricted in neurodevelopmental aberrations.</p>
<p>The PWS region of chromosome 15 has five paternally expressed genes, including <italic>MKRN3</italic>, <italic>MAGEL2</italic>, <italic>NDN</italic>, <italic>NPAP1</italic>, <italic>SNURF-SNRPN</italic>, which could encode polypeptides and a cluster of small nucleolar RNA genes (snoRNAs), which mediate post-transcriptional, sequence-specific methylation that dictates mRNA folding and stability [<xref ref-type="bibr" rid="ref18">18</xref><xref ref-type="bibr" rid="ref31">31</xref>]. The <italic>NDN</italic> gene encodes the protein necdin, which is vital for serotonergic and GABAergic neuron development, as well as central respiratory control [<xref ref-type="bibr" rid="ref32">32</xref><xref ref-type="bibr" rid="ref33">33</xref>]. The <italic>MAGEL2</italic> protein is highly expressed in the hypothalamic supraoptic, paraventricular, and suprachiasmatic nuclei. In fact, <italic>MAGEL2</italic> knockout mice demonstrated delayed pubertal onset and declined fertility, as well as decreased wakefulness and motor activity, which corroborates PWS patients [<xref ref-type="bibr" rid="ref34">34</xref>]. SNORD116 is one of the snoRNAs in the PWS region that accounts for several PWS phenotypes. SNORD116-null mice were anxious, deficient in motor learning, with growth retardation and moderate hyperphagia [<xref ref-type="bibr" rid="ref34">34</xref>]. SNORD116 microdeletions have been reported in three individuals, all exhibiting some cardinal features of PWS, including neonatal hypotonia, infantile feeding problems, rapid weight gain after 2 years of age, hyperphagia, hypogonadism, mental retardation, and speech and behavioral problems; however, these patients do not have typical facial features of PWS, as well as growth retardation [<xref ref-type="bibr" rid="ref2">2</xref>]. The clinical phenotypes of PWS are wide, including neurological, endocrinological, and metabolic symptoms, which are, perhaps, caused by the loss of expression of multiple functional genes on 15q11.2-q13.</p>
<p>The three major molecular mechanisms inducing PWS are paternal deletion (accounts for 65%–75% of patients), maternal UPD (20%–30% of patients), and imprinting defect (1%–3% of patients) [<xref ref-type="bibr" rid="ref2">2</xref>]. In Taiwan, a retrospective study conducted on 52 PWS patients revealed 45 (87%) with paternal deletion, 5 (10%) with maternal UPD, and 2 (4%) with an imprinting defect [<xref ref-type="bibr" rid="ref35">35</xref>]. The clinical phenotypes of patients with paternal deletions or maternal UPD differ. Patients with UPD are less likely to exhibit hypopigmentation or the characteristic facial appearance of PWS [<xref ref-type="bibr" rid="ref36">36</xref>]. As reported by researchers, patients with UPD had an elevated risk of psychiatric illness and bipolar disorder, whereas patients with paternal deletions had markedly lower full-scale IQ and verbal IQ [<xref ref-type="bibr" rid="ref37">37</xref>]. For AS patients, four different molecular defects include the deletion of maternal chromosome 15q11.2-q13 (75% of patients), paternal UPD (1%–2% of patients), imprinting defects (1%–3% of patients), and <italic>UBE3A</italic> mutations (5%–10% of patients) [<xref ref-type="bibr" rid="ref38">38</xref>]. Patients with AS induced by maternal deletions typically have relatively severe clinical manifestations, including microcephaly, seizures, and hypopigmentation, possibly caused by the haploinsufficiency of the downstream non-imprinted genes, including <italic>GABRB3</italic>, <italic>GABRA5</italic>, <italic>GABRG3</italic>, and <italic>OCA1</italic>. Patients with <italic>UBE3A</italic> mutations recapitulate all the core symptoms of AS, implying that the phenotypes of AS mostly correlate with <italic>UBE3A</italic> gene dysfunction [<xref ref-type="bibr" rid="ref16">16</xref>].</p>
</sec>
<sec id="sec1-4">
<title>S<sc>EIZURE PREVALENCE AND SEMIOLOGY OF PATIENTS WITH ANGELMAN SYNDROME AND PRADER–WILLI SYNDROME</sc></title>
<p>Although AS and PWS are sister imprinting disorders, the diverse molecular mechanisms distinguish their clinical phenotypes, including seizure prevalence and semiology. We summarized the prevalence of various seizure types in patients with AS and PWS [<xref ref-type="table" rid="T1">Table 1</xref>]. Epilepsy occurs in 75%–95% of AS patients and seizures could develop before the diagnosis of AS [<xref ref-type="bibr" rid="ref39">39</xref><xref ref-type="bibr" rid="ref40">40</xref><xref ref-type="bibr" rid="ref41">41</xref>]. The age of seizure onset may be early up to 3 months (mean onset age, 1–2 years) [<xref ref-type="bibr" rid="ref41">41</xref><xref ref-type="bibr" rid="ref42">42</xref>]. The seizure types of AS patients markedly vary and transform over time. Infantile spasm could be the first presentation of epilepsy in some AS patients [<xref ref-type="bibr" rid="ref39">39</xref><xref ref-type="bibr" rid="ref40">40</xref><xref ref-type="bibr" rid="ref42">42</xref>]. Other seizure types, including generalized tonic–clonic seizure (GTCS), absence seizures, febrile seizures (FS), myoclonic seizures, atonic seizures, and complex partial seizures, have also been observed, and over half of the AS patients have &gt;2 seizure types [<xref ref-type="bibr" rid="ref43">43</xref><xref ref-type="bibr" rid="ref44">44</xref><xref ref-type="bibr" rid="ref45">45</xref>]. The seizure frequency is high in AS patients and could occur &gt;10 times a week [<xref ref-type="bibr" rid="ref40">40</xref>]. Nonconvulsive status epilepticus (SE), such as atypical absence SE and myoclonic SE, are also frequently observed [<xref ref-type="bibr" rid="ref41">41</xref><xref ref-type="bibr" rid="ref42">42</xref><xref ref-type="bibr" rid="ref46">46</xref>]. Nonconvulsive SE could result in cognitive decline, which could misguide physicians and lead to the misdiagnosis of metabolic disorders [<xref ref-type="bibr" rid="ref41">41</xref>].</p>
<table-wrap id="T1" position="float">
<label>Table 1</label>
<caption>
<p>Prevalence of various seizure types in patients with AS and PWS</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1"></th>
<th align="center" colspan="1" rowspan="1">AS</th>
<th align="center" colspan="1" rowspan="1">PWS</th>
<th align="center" colspan="1" rowspan="1">Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Overall prevalence</td>
<td align="center" colspan="1" rowspan="1">75-95%</td>
<td align="center" colspan="1" rowspan="1">4-33%</td>
<td align="center" colspan="1" rowspan="1">
<xref ref-type="bibr" rid="ref39">39</xref>
<xref ref-type="bibr" rid="ref40">40</xref>
<xref ref-type="bibr" rid="ref41">41</xref>
<xref ref-type="bibr" rid="ref44">44</xref>
<xref ref-type="bibr" rid="ref47">47</xref>
<xref ref-type="bibr" rid="ref48">48</xref>
<xref ref-type="bibr" rid="ref49">49</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Atonic</td>
<td align="center" colspan="1" rowspan="1">4-41%</td>
<td align="center" colspan="1" rowspan="1">0-22%</td>
<td align="center" colspan="1" rowspan="1">
<xref ref-type="bibr" rid="ref40">40</xref>
<xref ref-type="bibr" rid="ref42">42</xref>
<xref ref-type="bibr" rid="ref44">44</xref>
<xref ref-type="bibr" rid="ref47">47</xref>
<xref ref-type="bibr" rid="ref48">48</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Generalized tonic-clonic</td>
<td align="center" colspan="1" rowspan="1">13-40%</td>
<td align="center" colspan="1" rowspan="1">60-88% *4% in 48</td>
<td align="center" colspan="1" rowspan="1"><xref ref-type="bibr" rid="ref40">40</xref><xref ref-type="bibr" rid="ref41">41</xref><xref ref-type="bibr" rid="ref42">42</xref><xref ref-type="bibr" rid="ref43">43</xref><xref ref-type="bibr" rid="ref44">44</xref><xref ref-type="bibr" rid="ref45">45</xref><xref ref-type="bibr" rid="ref48">48</xref>*<xref ref-type="bibr" rid="ref49">49</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Absence </td>
<td align="center" colspan="1" rowspan="1">26-37%</td>
<td align="center" colspan="1" rowspan="1">10-13%</td>
<td align="center" colspan="1" rowspan="1">
<xref ref-type="bibr" rid="ref40">40</xref>
<xref ref-type="bibr" rid="ref41">41</xref>
<xref ref-type="bibr" rid="ref43">43</xref>
<xref ref-type="bibr" rid="ref44">44</xref>
<xref ref-type="bibr" rid="ref49">49</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Complex partial</td>
<td align="center" colspan="1" rowspan="1">16-32%</td>
<td align="center" colspan="1" rowspan="1">10-11% *92% in 48</td>
<td align="center" colspan="1" rowspan="1"><xref ref-type="bibr" rid="ref40">40</xref><xref ref-type="bibr" rid="ref41">41</xref><xref ref-type="bibr" rid="ref47">47</xref><xref ref-type="bibr" rid="ref48">48</xref>*<xref ref-type="bibr" rid="ref49">49</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Myoclonic</td>
<td align="center" colspan="1" rowspan="1">12-36%</td>
<td align="center" colspan="1" rowspan="1">0-8%</td>
<td align="center" colspan="1" rowspan="1">
<xref ref-type="bibr" rid="ref40">40</xref>
<xref ref-type="bibr" rid="ref41">41</xref>
<xref ref-type="bibr" rid="ref42">42</xref>
<xref ref-type="bibr" rid="ref43">43</xref>
<xref ref-type="bibr" rid="ref48">48</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Tonic</td>
<td align="center" colspan="1" rowspan="1">9%</td>
<td align="center" colspan="1" rowspan="1">0</td>
<td align="center" colspan="1" rowspan="1">
<xref ref-type="bibr" rid="ref40">40</xref>
<xref ref-type="bibr" rid="ref47">47</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Secondarily generalized</td>
<td align="center" colspan="1" rowspan="1">8%</td>
<td align="center" colspan="1" rowspan="1">4%</td>
<td align="center" colspan="1" rowspan="1">
<xref ref-type="bibr" rid="ref40">40</xref>
<xref ref-type="bibr" rid="ref48">48</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Focal motor</td>
<td align="center" colspan="1" rowspan="1">6-17%</td>
<td align="center" colspan="1" rowspan="1">10%</td>
<td align="center" colspan="1" rowspan="1">
<xref ref-type="bibr" rid="ref40">40</xref>
<xref ref-type="bibr" rid="ref41">41</xref>
<xref ref-type="bibr" rid="ref43">43</xref>
<xref ref-type="bibr" rid="ref49">49</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Infantile spasms</td>
<td align="center" colspan="1" rowspan="1">2-9%</td>
<td align="center" colspan="1" rowspan="1">0</td>
<td align="center" colspan="1" rowspan="1">
<xref ref-type="bibr" rid="ref39">39</xref>
<xref ref-type="bibr" rid="ref40">40</xref>
<xref ref-type="bibr" rid="ref42">42</xref>
<xref ref-type="bibr" rid="ref47">47</xref>
<xref ref-type="bibr" rid="ref49">49</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Lennox-Gastaut syndrome</td>
<td align="center" colspan="1" rowspan="1">1%</td>
<td align="center" colspan="1" rowspan="1">0</td>
<td align="center" colspan="1" rowspan="1">
<xref ref-type="bibr" rid="ref40">40</xref>
<xref ref-type="bibr" rid="ref47">47</xref>
<xref ref-type="bibr" rid="ref49">49</xref>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>AS, Angelman syndrome; PWS, Prader-Willi syndrome. *Seizure types of PWS patients from the report by Vendrame <italic>et al</italic>. were inconsistent with other case series [<xref ref-type="bibr" rid="ref48">48</xref>]</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Conversely, a seizure occurs in only a minority of PWS patients (4%–33%) [<xref ref-type="bibr" rid="ref5">5</xref><xref ref-type="bibr" rid="ref44">44</xref><xref ref-type="bibr" rid="ref47">47</xref><xref ref-type="bibr" rid="ref48">48</xref><xref ref-type="bibr" rid="ref49">49</xref>]. In PWS patients, most seizures develop before the age of 6 years [<xref ref-type="bibr" rid="ref4">4</xref><xref ref-type="bibr" rid="ref5">5</xref><xref ref-type="bibr" rid="ref47">47</xref><xref ref-type="bibr" rid="ref48">48</xref>]; however, in some patients, the age of seizure onset is delayed to teenage years [<xref ref-type="bibr" rid="ref4">4</xref><xref ref-type="bibr" rid="ref48">48</xref>]. In a study examining 142 PWS patients in Japan, 31 experienced seizures, wherein FS accounted for 17 (12%) cases, and only 9 (6.3%) patients were diagnosed with epilepsy [<xref ref-type="bibr" rid="ref47">47</xref>]. In another cohort of 92 PWS patients in the United States, Vendrame <italic>et al.</italic> reported only 24 (26%) patients with epilepsy [<xref ref-type="bibr" rid="ref48">48</xref>]. The seizure types of PWS patients with epilepsy vary in the literature. As established by studies, GTCS is the leading seizure type of PWS patients with epilepsy [<xref ref-type="bibr" rid="ref4">4</xref><xref ref-type="bibr" rid="ref44">44</xref><xref ref-type="bibr" rid="ref47">47</xref><xref ref-type="bibr" rid="ref49">49</xref>]. However, 22 out of 24 PWS patients with epilepsy in a study had focal epilepsy, which mostly included staring spells with eye deviation [<xref ref-type="bibr" rid="ref48">48</xref>]. Typically, seizures in PWS patients are regarded a spectrum of generalized seizure disorder, including FS and GTCS [<xref ref-type="bibr" rid="ref49">49</xref>], in which SE is rarely observed, and patients with multiple seizure types are common [<xref ref-type="bibr" rid="ref4">4</xref><xref ref-type="bibr" rid="ref47">47</xref>].</p>
<p>Genotypes of both AS and PWS affect epilepsy phenotypes and severity. Those patients with AS caused by maternal deletion of chromosome 15q11.3-q13 would face a higher risk of epilepsy than those caused by <italic>UBE3A</italic> mutations or paternal UPD [<xref ref-type="bibr" rid="ref39">39</xref><xref ref-type="bibr" rid="ref46">46</xref>]. Shaaya <italic>et al.</italic> reported that 88% of patients with deletion have seizures, whereas 57% and 40% of patients with <italic>UBE3A</italic> mutations and paternal UPD have seizures, respectively [<xref ref-type="bibr" rid="ref39">39</xref>]. The interaction of <italic>UBE3A</italic> and <italic>GABRB3</italic> dysfunction due to maternal 15q11.3-q13 deletion was considered as the cause of high seizure burden in AS patients [<xref ref-type="bibr" rid="ref44">44</xref>], and the clinical speculation was in line with a recent study which illustrated the GABAergic <italic>UBE3A</italic> loss a principle cause of circuit hyperexcitability in AS mice [<xref ref-type="bibr" rid="ref50">50</xref>]. The genotype difference of seizure prevalence in PWS patients was reported in some studies. Fan <italic>et al.</italic> reported that PWS patients caused by paternal deletion are more likely to experience epilepsy (18%–45%) than those caused by maternal UPD (0%–7%), probably due to their haploinsufficiency of the GABA receptor subunit cluster (GABRB3, GABRA5, and GABRG3) [<xref ref-type="bibr" rid="ref49">49</xref>]. However, Takeshita <italic>et al.</italic> reported that 26 of 109 patients with deletion and 5 of 31 patients with maternal UPD experienced seizures (<italic>P</italic> = 0.35), which contradicts the findings in prior studies [<xref ref-type="bibr" rid="ref47">47</xref>]. Thus, larger cohort and meta-analyses are warranted to ascertain the correlation between epilepsy phenotypes and genotypes of PWS patients.</p>
</sec>
<sec id="sec1-5">
<title>E<sc>LECTROENCEPHALOGRAM CHARACTERISTICS OF EPILEPSY WITH ANGELMAN SYNDROME AND PRADER–WILLI SYNDROME</sc></title>
<p>In a case series, Boyd <italic>et al.</italic> extensively investigated the EEG characteristics of epilepsy in AS patients [<xref ref-type="bibr" rid="ref51">51</xref>]; they recognized three patterns of EEG abnormalities in 19 children with AS, which are categorized by slow waves over different brain regions as follows: Pattern 1 – prolonged runs of rhythmically triphasic 2–3-Hz activity (200–500 μV) often more prominent anteriorly, sometimes associated with discharges (ill-defined spike/wave complexes); Pattern 2 – spikes mixed with 3–4-Hz components usually &gt;200 μV mainly posteriorly and facilitated by, or only observed with, eye closure [<xref ref-type="fig" rid="F2">Figure 2</xref>]; and Pattern 3 – persistent rhythmic 4–6-Hz activities reaching &gt;200 μV not related to drowsiness. These three EEG patterns have been validated in follow-up studies, and pattern 1 was observed in 60%–80% of AS patients, which persisted until adulthood [<xref ref-type="bibr" rid="ref44">44</xref><xref ref-type="bibr" rid="ref52">52</xref><xref ref-type="bibr" rid="ref53">53</xref>]. Individual AS patients would have more than one EEG pattern in the same recording or at a different time, and the EEG patterns did not correspond with specific types of epilepsy [<xref ref-type="bibr" rid="ref44">44</xref><xref ref-type="bibr" rid="ref52">52</xref>]. In patients who possessed generalized high-voltage slow-wave background activities, it was difficult to control seizures [<xref ref-type="bibr" rid="ref54">54</xref>]. Except for slow activities, hypsarrhythmia and continuous diffuse spikes and waves also occur in young AS patients, which corresponded with clinical infantile spasms and atypical absence SE, respectively [<xref ref-type="bibr" rid="ref42">42</xref>]. Arguably, hypsarrhythmia in AS patients comprises runs of delta activities intermixing multifocal spikes or sharp waves. Compared with typical hypsarrhythmia in West syndrome, AS patients lack the fragmentation of hypsarrhythmia during sleep, with no sleep/wake correlation [<xref ref-type="bibr" rid="ref55">55</xref><xref ref-type="bibr" rid="ref56">56</xref>]. Conclusively, EEG is a sensitive tool for the early diagnosis of AS because of characteristic patterns, offering the opportunity of early etiological diagnosis [<xref ref-type="bibr" rid="ref56">56</xref>].</p>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption>
<p>Awake electroencephalography in a 5-year-old boy with Angelman syndrome. The recording shows posteriorly-dominated 3–4-Hz high-voltage slow waves, which are characteristic for Angelman syndrome patients</p>
</caption>
<graphic xlink:href="TCMJ-32-137-g002"></graphic>
</fig>
<p>In PWS patients with epilepsy, no typical EEG pattern has been observed [<xref ref-type="bibr" rid="ref4">4</xref>]. Unlike AS patients, few PWS patients with epilepsy have slow EEG background activities and the triphasic high-voltage, anterior-dominated delta waves [<xref ref-type="bibr" rid="ref4">4</xref><xref ref-type="bibr" rid="ref49">49</xref>], except Wang <italic>et al.</italic> reporting 5 PWS patients presenting persistent high-voltage 4–6-Hz activities [<xref ref-type="bibr" rid="ref44">44</xref>]. As per reports by researchers, interictal EEG recordings reveal focal, multifocal, or generalized epileptiform discharges [<xref ref-type="fig" rid="F3">Figure 3</xref>], per individual's seizure types [<xref ref-type="bibr" rid="ref4">4</xref><xref ref-type="bibr" rid="ref47">47</xref><xref ref-type="bibr" rid="ref48">48</xref>]. Ictal EEG has been scarcely reported. Verrotti <italic>et al.</italic> reported ictal EEG recording in 10 patients, and all had generalized spike-wave paroxysms related to GTCS, corroborating that GTCS is more common in PWS patients with epilepsy [<xref ref-type="bibr" rid="ref4">4</xref>].</p>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption>
<p>Sleep electroencephalography in a 2-year-old boy with Prader–Willi syndrome. The recording shows a short burst of generalized spike-waves and excessive beta activities over posterior head regions</p>
</caption>
<graphic xlink:href="TCMJ-32-137-g003"></graphic>
</fig>
</sec>
<sec id="sec1-6">
<title>S<sc>EIZURE TREATMENT AND PROGNOSIS FOR PATIENTS WITH ANGELMAN SYNDROME AND PRADER–WILLI SYNDROME</sc></title>
<p>For AS patients, controlling seizures is difficult with pharmacological treatment [<xref ref-type="bibr" rid="ref55">55</xref>]. In a large cohort of 461 AS patients, Thibert <italic>et al.</italic> reported that 77% of patients with epilepsy are refractory to antiepileptic drugs (AED), and only 15% respond well to the first AED [<xref ref-type="bibr" rid="ref40">40</xref>]. In most case series, AED polytherapy is required for better seizure control in most patients [<xref ref-type="bibr" rid="ref39">39</xref><xref ref-type="bibr" rid="ref40">40</xref><xref ref-type="bibr" rid="ref43">43</xref>]. The efficacy of each AED differs in the literature. Valproate (VPA) is the leading first-line AED and is highly effective, although adverse effects also frequently develop [<xref ref-type="bibr" rid="ref39">39</xref><xref ref-type="bibr" rid="ref41">41</xref><xref ref-type="bibr" rid="ref45">45</xref>]. VPA was effective in all 25 AS patients as mono- or poly-therapy; Shaaya <italic>et al.</italic> reported that 66.7% of patients experienced 90% seizure reduction, while 33.3% experienced 50% seizure reduction by VPA. However, 72% of patients developed adverse effects, including increased tremor, ataxia, and decline in motor skills. The adverse effects on motor ability result in a low-retention rate of VPA to 40% for AS patients [<xref ref-type="bibr" rid="ref39">39</xref>]. Furthermore, other serious adverse effects, such as pancreatitis and decreased platelets or white blood cells, have also been reported [<xref ref-type="bibr" rid="ref40">40</xref>].</p>
<p>New-generation AEDs, including levetiracetam (LEV), lamotrigine (LTG), and topiramate (TPM), are often prescribed for AS patients with epilepsy. Shaaya <italic>et al.</italic> reported prescribing LEV to 67% of patients, and 86% of patients exhibited a &gt;90% seizure reduction. They reported that the retention rate of LEV was 79%, while 21% of patients developed adverse effects, primarily behavioral changes [<xref ref-type="bibr" rid="ref39">39</xref>]. Thibert <italic>et al.</italic> reported that LEV was selected by 18% of participants and was the second most effective AED [<xref ref-type="bibr" rid="ref40">40</xref>]. Shaaya <italic>et al.</italic> reported the efficacy of LTG in 18 of 29 patients and correlated it with the retention rate at 67% [<xref ref-type="bibr" rid="ref39">39</xref>]. Notably, 12% and 13% of patients being administrated LEV and LTG experience seizure exacerbation, respectively [<xref ref-type="bibr" rid="ref40">40</xref>]. Franz <italic>et al.</italic> reported that five AS patients were successfully treated with TPM, which was well tolerated [<xref ref-type="bibr" rid="ref57">57</xref>]. Moreover, TPM is an effective AED as per Shaaya <italic>et al.</italic>'s series, but it often results in adverse effects such as fatigue, irritability, and loss of appetite; the TPM retention rate was 33%, and no patient received monotherapy with TPM [<xref ref-type="bibr" rid="ref39">39</xref>]. Benzodiazepines, including clonazepam (CZP) and clobazam (CLB), effectively controlled seizures in AS patients with epilepsy [<xref ref-type="bibr" rid="ref39">39</xref><xref ref-type="bibr" rid="ref40">40</xref><xref ref-type="bibr" rid="ref45">45</xref>]. Shaaya <italic>et al.</italic> reported that out of 51% of patients undergoing treatment with CLB administration, 93% exhibited &gt;90% seizure reduction, and 31% could be treated with CLB monotherapy. Moreover, side effects, such as sluggishness and aggression, were reported by 34% of patients regarding CLB; the CLB retention rate was 75% [<xref ref-type="bibr" rid="ref39">39</xref>]. Thibert <italic>et al.</italic> reported that CZP has a seizure freedom rate of 24% and high tolerability. Common adverse effects, such as fatigue and hypotonia, have been reported in 8% and 6% of patients who underwent treatment, respectively [<xref ref-type="bibr" rid="ref40">40</xref>]. Furthermore, CLB and CZP even exerted positive effects on patients’ alertness and behavior in a study [<xref ref-type="bibr" rid="ref45">45</xref>].</p>
<p>According to certain studies, some AEDs exaggerated seizures and even induced nonconvulsive SE in AS patients with epilepsy, including carbamazepine, oxcarbazepine, and vigabatrin [<xref ref-type="bibr" rid="ref41">41</xref><xref ref-type="bibr" rid="ref55">55</xref>]. Moreover, phenobarbital was less effective and 32% of patients developed intolerable side effects [<xref ref-type="bibr" rid="ref40">40</xref>]. The treatment experience with nonpharmacological treatments, including ketogenic diet, low glycemic index therapy (LGIT), and vagus nerve stimulation, is rare. Thibert <italic>et al.</italic> treated 8% of patients with a ketogenic diet, and only one-third reported effective results. Reportedly, the retention rate of the ketogenic diet was only 19% [<xref ref-type="bibr" rid="ref40">40</xref>]. Furthermore, LGIT was effective in 10 of 12 patients in Shaaya <italic>et al.</italic>'s series, and the patients also exhibited better tolerability (retention rate, 67%) [<xref ref-type="bibr" rid="ref39">39</xref>].</p>
<p>Compared with AS patients with epilepsy, seizures in PWS patients are less common and easy to treat. In some studies, FS was the leading etiology and did not require treatment, in addition, some patients had rare seizures for which rectal diazepam was used as necessary [<xref ref-type="bibr" rid="ref4">4</xref><xref ref-type="bibr" rid="ref5">5</xref><xref ref-type="bibr" rid="ref47">47</xref>]. Monotherapy with VPA, LEV, LTG, TPM resulted in good seizure control in PWS patients with epilepsy [<xref ref-type="bibr" rid="ref4">4</xref><xref ref-type="bibr" rid="ref48">48</xref>]. Unlike CBZ in AS patients, which may induce seizure aggravation, CBZ was effective in PWS patients and also correlated with good tolerability [<xref ref-type="bibr" rid="ref4">4</xref><xref ref-type="bibr" rid="ref47">47</xref><xref ref-type="bibr" rid="ref48">48</xref>].</p>
<p>The evolution of seizures is favorable in PWS patients but undetermined in AS. Although AS patients commonly develop seizures since infancy, and the seizures are typically challenging to control pharmacologically, these improve with time in some patients [<xref ref-type="bibr" rid="ref42">42</xref><xref ref-type="bibr" rid="ref43">43</xref>]. Sueri <italic>et al.</italic> reported that 27 out of 42 (64%) AS patients with epilepsy become seizure free at a median age of 10 years [<xref ref-type="bibr" rid="ref43">43</xref>]. Uemura <italic>et al.</italic> reported that 19 out of 22 patients (82.6%) were seizure free for, at least, 3 years in the last follow-up [<xref ref-type="bibr" rid="ref42">42</xref>]. Conversely, Laan <italic>et al.</italic> reported that epileptic seizures persisted in 13 out of 14 (92%) adult AS patients [<xref ref-type="bibr" rid="ref53">53</xref>]. For PWS patients with epilepsy, freedom from seizures was attained in 20 out of 24 (83.3%) patients [<xref ref-type="bibr" rid="ref48">48</xref>] and 32 out of 38 (84.2%) patients [<xref ref-type="bibr" rid="ref4">4</xref>] in different studies.</p>
<p>Several clinical trials toward AS and PWS were executed in recent years. Two clinical trials that strove to improve neurodevelopment in AS using minocycline and levodopa have been unsuccessful [<xref ref-type="bibr" rid="ref58">58</xref><xref ref-type="bibr" rid="ref59">59</xref>]. A Phase II study for AS using gaboxadol (OV101) which is a highly selective extrasynaptic GABA receptor agonist is ongoing. Gaboxadol may restore the deficit in GABAergic tonic inhibition of AS patients and possibly benefit to their neurodevelopment and seizure control [<xref ref-type="bibr" rid="ref8">8</xref>]. Two mechanistic approaches directly inhibiting SNHG-14 (UBE3A-ATS) with topoisomerase inhibitors or antisense oligonucleotides were developed from AS mouse models, and both would partially restore UBE3A protein [<xref ref-type="bibr" rid="ref60">60</xref><xref ref-type="bibr" rid="ref61">61</xref>]. The progress from the animal studies made the mechanistic treatment possible in the near future. For PWS, several new drugs revealed good efficacy on appetite control and weight loss, including exenatide [<xref ref-type="bibr" rid="ref62">62</xref>], beloranid [<xref ref-type="bibr" rid="ref63">63</xref>], and AZP-531 [<xref ref-type="bibr" rid="ref6">6</xref>], but their effects for neuropsychological phenotypes of PWS were undetermined. OXT is one of the primary targets for intervention due to decreased OXT-expressing neurons in PWS patients and animal models [<xref ref-type="bibr" rid="ref64">64</xref><xref ref-type="bibr" rid="ref65">65</xref>]. Intranasal OXT administration improved feeding and social skills in infants and also appetite control and behavior in children with PWS [<xref ref-type="bibr" rid="ref7">7</xref><xref ref-type="bibr" rid="ref66">66</xref>]. The long-term effects of OXT for neuropsychiatric symptoms of PWS are promising.</p>
</sec>
<sec id="sec1-7" sec-type="conclusions">
<title>C<sc>ONCLUSIONS</sc></title>
<p>Although AS and PWS are both chromosome 15q11.3-q13 dysfunctions, the molecular mechanisms differ in both congenital neurodevelopmental disorders because of genomic imprinting. Early diagnosis and teamwork intervention, including geneticists, neurologists, rehabilitation physicians, and pulmonologists, are important. PWS patients exhibit unique endocrinological and behavioral phenotypes, including short and obese figures, hyperphagia, autism, or OCD-like behaviors. Hypotonia, poor feeding, failure to thrive, and typical facial features are key points for the early diagnosis of PWS. Epilepsy is not common and easy to treat for PWS patients. However, AS patients develop epilepsy in their early lives, and the seizures are more difficult to control. The distinctive gait pattern and excessive laughter, as well as characteristic EEG patterns, result in the early suspicion and diagnosis of AS. Notably, AED polytherapy, including the combination of VPA, LEV, LTG, and BDZ, is often required to control seizures in AS patients. Moreover, CBZ, OXC, and VGB should be avoided and may induce nonconvulsive SE. Under proper treatment, seizures could be controlled well since late childhood or early adulthood for both AS and PWS patients.</p>
<sec id="sec2-1">
<title>Financial support and sponsorship</title>
<p>This study was supported by Taipei Tzu Chi General Hospital TCRD-TPE-104-39 to Shi-Bing Wong.</p>
</sec>
<sec id="sec2-2" sec-type="COI-statement">
<title>Conflicts of interest</title>
<p>There are no conflicts of interest.</p>
</sec>
</sec>
</body>
<back>
<ref-list>
<title>R<sc>EFERENCES</sc></title>
<ref id="ref1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cassidy</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>Dykens</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>CA</given-names>
</name>
</person-group>
<article-title>Prader-Willi and Angelman syndromes: Sister imprinted disorders</article-title>
<source/>Am J Med Genet
          <year>2000</year>
<volume>97</volume>
<fpage>136</fpage>
<lpage>46</lpage>
<pub-id pub-id-type="pmid">11180221</pub-id>
</element-citation>
</ref>
<ref id="ref2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cassidy</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>Schwartz</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Driscoll</surname>
<given-names>DJ</given-names>
</name>
</person-group>
<article-title>Prader-Willi syndrome</article-title>
<source/>Genet Med
          <year>2012</year>
<volume>14</volume>
<fpage>10</fpage>
<lpage>26</lpage>
<pub-id pub-id-type="pmid">22237428</pub-id>
</element-citation>
</ref>
<ref id="ref3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fiumara</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pittalà</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cocuzza</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sorge</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Epilepsy in patients with Angelman syndrome</article-title>
<source/>Ital J Pediatr
          <year>2010</year>
<volume>36</volume>
<fpage>31</fpage>
<pub-id pub-id-type="pmid">20398390</pub-id>
</element-citation>
</ref>
<ref id="ref4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Verrotti</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cusmai</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Laino</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Carotenuto</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Esposito</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Falsaperla</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Long-term outcome of epilepsy in patients with Prader-Willi syndrome</article-title>
<source/>J Neurol
          <year>2015</year>
<volume>262</volume>
<fpage>116</fpage>
<lpage>23</lpage>
<pub-id pub-id-type="pmid">25326049</pub-id>
</element-citation>
</ref>
<ref id="ref5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gilboa</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Gross-Tsur</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Epilepsy in Prader-Willi syndrome: Experience of a national referral centre</article-title>
<source/>Dev Med Child Neurol
          <year>2013</year>
<volume>55</volume>
<fpage>857</fpage>
<lpage>61</lpage>
<pub-id pub-id-type="pmid">23750756</pub-id>
</element-citation>
</ref>
<ref id="ref6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Allas</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Caixàs</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Poitou</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Coupaye</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Thuilleaux</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Lorenzini</surname>
<given-names>F</given-names>
</name>
<etal></etal>
</person-group>
<article-title>AZP-531, an unacylated ghrelin analog, improves food-related behavior in patients with Prader-Willi syndrome: A randomized placebo-controlled trial</article-title>
<source/>PLoS One
          <year>2018</year>
<volume>13</volume>
<fpage>e0190849</fpage>
<pub-id pub-id-type="pmid">29320575</pub-id>
</element-citation>
</ref>
<ref id="ref7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tauber</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Boulanouar</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Diene</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Çabal-Berthoumieu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ehlinger</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Fichaux-Bourin</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The use of oxytocin to improve feeding and social skills in infants with Prader-Willi syndrome</article-title>
<source/>Pediatrics
          <year>2017</year>
<fpage>139</fpage>
<comment>pii: e20162976</comment>
</element-citation>
</ref>
<ref id="ref8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ochoa-Lubinoff</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wink</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Grieco</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Visootsak</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Burdine</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kolevzon</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>STARS: STARS: A Phase 2 Adult Angelman Syndrome Clinical Trial: Randomized, Double-blind, Safety and Efficacy Study of Gaboxadol (P3.302)</article-title>
<source/>Neurology
          <year>2018</year>
<volume>90</volume>
<issue>15 Suppl</issue>
<fpage>302</fpage>
</element-citation>
</ref>
<ref id="ref9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vu</surname>
<given-names>TH</given-names>
</name>
<name>
<surname>Hoffman</surname>
<given-names>AR</given-names>
</name>
</person-group>
<article-title>Imprinting of the angelman syndrome gene, UBE3A, is restricted to brain</article-title>
<source/>Nat Genet
          <year>1997</year>
<volume>17</volume>
<fpage>12</fpage>
<lpage>3</lpage>
<pub-id pub-id-type="pmid">9288087</pub-id>
</element-citation>
</ref>
<ref id="ref10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsuura</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Sutcliffe</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Galjaard</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>YH</given-names>
</name>
<name>
<surname>Benton</surname>
<given-names>CS</given-names>
</name>
<etal></etal>
</person-group>
<article-title><italic>De novo</italic> truncating mutations in E6-AP ubiquitin-protein ligase gene (UBE3A) in Angelman syndrome</article-title>
<source/>Nat Genet
          <year>1997</year>
<volume>15</volume>
<fpage>74</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="pmid">8988172</pub-id>
</element-citation>
</ref>
<ref id="ref11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kishino</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Lalande</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wagstaff</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>UBE3A/E6-AP mutations cause Angelman syndrome</article-title>
<source/>Nat Genet
          <year>1997</year>
<volume>15</volume>
<fpage>70</fpage>
<lpage>3</lpage>
<pub-id pub-id-type="pmid">8988171</pub-id>
</element-citation>
</ref>
<ref id="ref12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tan</surname>
<given-names>WH</given-names>
</name>
<name>
<surname>Bacino</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Skinner</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Anselm</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Barbieri-Welge</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Bauer-Carlin</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Angelman syndrome: Mutations influence features in early childhood</article-title>
<source/>Am J Med Genet A
          <year>2011</year>
<volume>155A</volume>
<fpage>81</fpage>
<lpage>90</lpage>
<pub-id pub-id-type="pmid">21204213</pub-id>
</element-citation>
</ref>
<ref id="ref13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zori</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Mattei</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Moncla</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Parental origin of del (15)(q11-q13) in Angelman and Prader-Willi syndromes</article-title>
<source/>Am J Med Genet
          <year>1990</year>
<volume>37</volume>
<fpage>294</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="pmid">2248305</pub-id>
</element-citation>
</ref>
<ref id="ref14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Williams</surname>
<given-names>CA</given-names>
</name>
</person-group>
<article-title>The behavioral phenotype of the Angelman syndrome</article-title>
<source/>Am J Med Genet C Semin Med Genet
          <year>2010</year>
<volume>154C</volume>
<fpage>432</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="pmid">20981772</pub-id>
</element-citation>
</ref>
<ref id="ref15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Larson</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Shinnick</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Shaaya</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Thiele</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Thibert</surname>
<given-names>RL</given-names>
</name>
</person-group>
<article-title>Angelman syndrome in adulthood</article-title>
<source/>Am J Med Genet A
          <year>2015</year>
<volume>167A</volume>
<fpage>331</fpage>
<lpage>44</lpage>
<pub-id pub-id-type="pmid">25428759</pub-id>
</element-citation>
</ref>
<ref id="ref16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buiting</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Horsthemke</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Angelman syndrome – Insights into a rare neurogenetic disorder</article-title>
<source/>Nat Rev Neurol
          <year>2016</year>
<volume>12</volume>
<fpage>584</fpage>
<lpage>93</lpage>
<pub-id pub-id-type="pmid">27615419</pub-id>
</element-citation>
</ref>
<ref id="ref17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cassidy</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>Driscoll</surname>
<given-names>DJ</given-names>
</name>
</person-group>
<article-title>Prader-Willi syndrome</article-title>
<source/>Eur J Hum Genet
          <year>2009</year>
<volume>17</volume>
<fpage>3</fpage>
<lpage>13</lpage>
<pub-id pub-id-type="pmid">18781185</pub-id>
</element-citation>
</ref>
<ref id="ref18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Irizarry</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Freemark</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Haqq</surname>
<given-names>AM</given-names>
</name>
</person-group>
<article-title>Prader Willi syndrome: Genetics, metabolomics, hormonal function, and new approaches to therapy</article-title>
<source/>Adv Pediatr
          <year>2016</year>
<volume>63</volume>
<fpage>47</fpage>
<lpage>77</lpage>
<pub-id pub-id-type="pmid">27426895</pub-id>
</element-citation>
</ref>
<ref id="ref19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Veltman</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Craig</surname>
<given-names>EE</given-names>
</name>
<name>
<surname>Bolton</surname>
<given-names>PF</given-names>
</name>
</person-group>
<article-title>Autism spectrum disorders in Prader-Willi and Angelman syndromes: A systematic review</article-title>
<source/>Psychiatr Genet
          <year>2005</year>
<volume>15</volume>
<fpage>243</fpage>
<lpage>54</lpage>
<pub-id pub-id-type="pmid">16314754</pub-id>
</element-citation>
</ref>
<ref id="ref20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schwartz</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Holland</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Dykens</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Strong</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Roof</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Bohonowych</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Prader-Willi syndrome mental health research strategy workshop proceedings: The state of the science and future directions</article-title>
<source/>Orphanet J Rare Dis
          <year>2016</year>
<volume>11</volume>
<fpage>131</fpage>
<pub-id pub-id-type="pmid">27682995</pub-id>
</element-citation>
</ref>
<ref id="ref21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jauregi</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Laurier</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Copet</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Tauber</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Thuilleaux</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Behavioral profile of adults with Prader-Willi syndrome: Correlations with individual and environmental variables</article-title>
<source/>J Neurodev Disord
          <year>2013</year>
<volume>5</volume>
<fpage>18</fpage>
<pub-id pub-id-type="pmid">23919902</pub-id>
</element-citation>
</ref>
<ref id="ref22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sinnema</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Einfeld</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Schrander-Stumpel</surname>
<given-names>CT</given-names>
</name>
<name>
<surname>Maaskant</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Boer</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Curfs</surname>
<given-names>LM</given-names>
</name>
</person-group>
<article-title>Behavioral phenotype in adults with Prader-Willi syndrome</article-title>
<source/>Res Dev Disabil
          <year>2011</year>
<volume>32</volume>
<fpage>604</fpage>
<lpage>12</lpage>
<pub-id pub-id-type="pmid">21227640</pub-id>
</element-citation>
</ref>
<ref id="ref23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hiraiwa</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Maegaki</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Oka</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ohno</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Behavioral and psychiatric disorders in Prader-Willi syndrome: A population study in Japan</article-title>
<source/>Brain Dev
          <year>2007</year>
<volume>29</volume>
<fpage>535</fpage>
<lpage>42</lpage>
<pub-id pub-id-type="pmid">17314021</pub-id>
</element-citation>
</ref>
<ref id="ref24">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Butler</surname>
<given-names>JV</given-names>
</name>
<name>
<surname>Whittington</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Holland</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Boer</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Clarke</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Webb</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Prevalence of, and risk factors for, physical ill-health in people with Prader-Willi syndrome: A population-based study</article-title>
<source/>Dev Med Child Neurol
          <year>2002</year>
<volume>44</volume>
<fpage>248</fpage>
<lpage>55</lpage>
<pub-id pub-id-type="pmid">11995893</pub-id>
</element-citation>
</ref>
<ref id="ref25">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Monk</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Mackay</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Eggermann</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Maher</surname>
<given-names>ER</given-names>
</name>
<name>
<surname>Riccio</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Genomic imprinting disorders: Lessons on how genome, epigenome and environment interact</article-title>
<source/>Nat Rev Genet
          <year>2019</year>
<volume>20</volume>
<fpage>235</fpage>
<lpage>48</lpage>
<pub-id pub-id-type="pmid">30647469</pub-id>
</element-citation>
</ref>
<ref id="ref26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peters</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>The role of genomic imprinting in biology and disease: An expanding view</article-title>
<source/>Nat Rev Genet
          <year>2014</year>
<volume>15</volume>
<fpage>517</fpage>
<lpage>30</lpage>
<pub-id pub-id-type="pmid">24958438</pub-id>
</element-citation>
</ref>
<ref id="ref27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Horsthemke</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>In brief: Genomic imprinting and imprinting diseases</article-title>
<source/>J Pathol
          <year>2014</year>
<volume>232</volume>
<fpage>485</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="pmid">24395592</pub-id>
</element-citation>
</ref>
<ref id="ref28">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nicholls</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Knoll</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Butler</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Karam</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lalande</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Genetic imprinting suggested by maternal heterodisomy in nondeletion Prader-Willi syndrome</article-title>
<source/>Nature
          <year>1989</year>
<volume>342</volume>
<fpage>281</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="pmid">2812027</pub-id>
</element-citation>
</ref>
<ref id="ref29">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meng</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Person</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Beaudet</surname>
<given-names>AL</given-names>
</name>
</person-group>
<article-title>Ube3a-ATS is an atypical RNA polymerase II transcript that represses the paternal expression of Ube3a</article-title>
<source/>Hum Mol Genet
          <year>2012</year>
<volume>21</volume>
<fpage>3001</fpage>
<lpage>12</lpage>
<pub-id pub-id-type="pmid">22493002</pub-id>
</element-citation>
</ref>
<ref id="ref30">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Runte</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kroisel</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Gillessen-Kaesbach</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Varon</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Horn</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>MY</given-names>
</name>
<etal></etal>
</person-group>
<article-title>SNURF-SNRPN and UBE3A transcript levels in patients with Angelman syndrome</article-title>
<source/>Hum Genet
          <year>2004</year>
<volume>114</volume>
<fpage>553</fpage>
<lpage>61</lpage>
<pub-id pub-id-type="pmid">15014980</pub-id>
</element-citation>
</ref>
<ref id="ref31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ehrhart</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Janssen</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>Coort</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Evelo</surname>
<given-names>CT</given-names>
</name>
<name>
<surname>Curfs</surname>
<given-names>LM</given-names>
</name>
</person-group>
<article-title>Prader-Willi syndrome and Angelman syndrome: Visualisation of the molecular pathways for two chromosomal disorders World</article-title>
<source/>J Biol Psychiatry
          <year>2018</year>
<volume>1</volume>
<fpage>13</fpage>
</element-citation>
</ref>
<ref id="ref32">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zanella</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Watrin</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Mebarek</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Marly</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Roussel</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gire</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Necdin plays a role in the serotonergic modulation of the mouse respiratory network: Implication for Prader-Willi syndrome</article-title>
<source/>J Neurosci
          <year>2008</year>
<volume>28</volume>
<fpage>1745</fpage>
<lpage>55</lpage>
<pub-id pub-id-type="pmid">18272695</pub-id>
</element-citation>
</ref>
<ref id="ref33">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuwajima</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nishimura</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Yoshikawa</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Necdin promotes GABAergic neuron differentiation in cooperation with dlx homeodomain proteins</article-title>
<source/>J Neurosci
          <year>2006</year>
<volume>26</volume>
<fpage>5383</fpage>
<lpage>92</lpage>
<pub-id pub-id-type="pmid">16707790</pub-id>
</element-citation>
</ref>
<ref id="ref34">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bervini</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Herzog</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Mouse models of Prader-Willi syndrome: A systematic review</article-title>
<source/>Front Neuroendocrinol
          <year>2013</year>
<volume>34</volume>
<fpage>107</fpage>
<lpage>19</lpage>
<pub-id pub-id-type="pmid">23391702</pub-id>
</element-citation>
</ref>
<ref id="ref35">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>HY</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Yen</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>YJ</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>CY</given-names>
</name>
<name>
<surname>Hung</surname>
<given-names>HY</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Prader-Willi syndrome in Taiwan</article-title>
<source/>Pediatr Int
          <year>2007</year>
<volume>49</volume>
<fpage>375</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">17532839</pub-id>
</element-citation>
</ref>
<ref id="ref36">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gillessen-Kaesbach</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Robinson</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Lohmann</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Kaya-Westerloh</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Passarge</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Horsthemke</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Genotype-phenotype correlation in a series of 167 deletion and non-deletion patients with Prader-Willi syndrome</article-title>
<source/>Hum Genet
          <year>1995</year>
<volume>96</volume>
<fpage>638</fpage>
<lpage>43</lpage>
<pub-id pub-id-type="pmid">8522319</pub-id>
</element-citation>
</ref>
<ref id="ref37">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zhan</surname>
<given-names>GD</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>GY</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Psychiatric illness and intellectual disability in the Prader-Willi syndrome with different molecular defects – A meta analysis</article-title>
<source/>PLoS One
          <year>2013</year>
<volume>8</volume>
<fpage>e72640</fpage>
<pub-id pub-id-type="pmid">23967326</pub-id>
</element-citation>
</ref>
<ref id="ref38">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buiting</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Clayton-Smith</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Driscoll</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Gillessen-Kaesbach</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Kanber</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Schwinger</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Clinical utility gene card for: Angelman Syndrome</article-title>
<source/>Eur J Hum Genet
          <year>2015</year>
<fpage>23</fpage>
</element-citation>
</ref>
<ref id="ref39">
<label>39</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shaaya</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Grocott</surname>
<given-names>OR</given-names>
</name>
<name>
<surname>Laing</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Thibert</surname>
<given-names>RL</given-names>
</name>
</person-group>
<article-title>Seizure treatment in Angelman syndrome: A case series from the Angelman syndrome clinic at massachusetts general hospital</article-title>
<source/>Epilepsy Behav
          <year>2016</year>
<volume>60</volume>
<fpage>138</fpage>
<lpage>41</lpage>
<pub-id pub-id-type="pmid">27206232</pub-id>
</element-citation>
</ref>
<ref id="ref40">
<label>40</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thibert</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Conant</surname>
<given-names>KD</given-names>
</name>
<name>
<surname>Braun</surname>
<given-names>EK</given-names>
</name>
<name>
<surname>Bruno</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Said</surname>
<given-names>RR</given-names>
</name>
<name>
<surname>Nespeca</surname>
<given-names>MP</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Epilepsy in Angelman syndrome: A questionnaire-based assessment of the natural history and current treatment options</article-title>
<source/>Epilepsia
          <year>2009</year>
<volume>50</volume>
<fpage>2369</fpage>
<lpage>76</lpage>
<pub-id pub-id-type="pmid">19453717</pub-id>
</element-citation>
</ref>
<ref id="ref41">
<label>41</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Valente</surname>
<given-names>KD</given-names>
</name>
<name>
<surname>Koiffmann</surname>
<given-names>CP</given-names>
</name>
<name>
<surname>Fridman</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Varella</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kok</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Andrade</surname>
<given-names>JQ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Epilepsy in patients with Angelman syndrome caused by deletion of the chromosome 15q11-13</article-title>
<source/>Arch Neurol
          <year>2006</year>
<volume>63</volume>
<fpage>122</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">16401744</pub-id>
</element-citation>
</ref>
<ref id="ref42">
<label>42</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uemura</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Matsumoto</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nakamura</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Watanabe</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Negoro</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kumagai</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Evolution of seizures and electroencephalographical findings in 23 cases of deletion type Angelman syndrome</article-title>
<source/>Brain Dev
          <year>2005</year>
<volume>27</volume>
<fpage>383</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">15963670</pub-id>
</element-citation>
</ref>
<ref id="ref43">
<label>43</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sueri</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ferlazzo</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Elia</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bonanni</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Randazzo</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Gasparini</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Epilepsy and sleep disorders improve in adolescents and adults with Angelman syndrome: A multicenter study on 46 patients</article-title>
<source/>Epilepsy Behav
          <year>2017</year>
<volume>75</volume>
<fpage>225</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">28827041</pub-id>
</element-citation>
</ref>
<ref id="ref44">
<label>44</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Hou</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Sue</surname>
<given-names>WC</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>WT</given-names>
</name>
</person-group>
<article-title>Electroclinical characteristics of seizures-comparing Prader-willi syndrome with Angelman syndrome</article-title>
<source/>Brain Dev
          <year>2005</year>
<volume>27</volume>
<fpage>101</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="pmid">15668048</pub-id>
</element-citation>
</ref>
<ref id="ref45">
<label>45</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ruggieri</surname>
<given-names>M</given-names>
</name>
<name>
<surname>McShane</surname>
<given-names>MA</given-names>
</name>
</person-group>
<article-title>Parental view of epilepsy in Angelman syndrome: A questionnaire study</article-title>
<source/>Arch Dis Child
          <year>1998</year>
<volume>79</volume>
<fpage>423</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="pmid">10193256</pub-id>
</element-citation>
</ref>
<ref id="ref46">
<label>46</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Minassian</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>DeLorey</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Olsen</surname>
<given-names>RW</given-names>
</name>
<name>
<surname>Philippart</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bronstein</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Angelman syndrome: Correlations between epilepsy phenotypes and genotypes</article-title>
<source/>Ann Neurol
          <year>1998</year>
<volume>43</volume>
<fpage>485</fpage>
<lpage>93</lpage>
<pub-id pub-id-type="pmid">9546330</pub-id>
</element-citation>
</ref>
<ref id="ref47">
<label>47</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takeshita</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Murakami</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Sakuta</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Nagai</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Evaluating the frequency and characteristics of seizures in 142 Japanese patients with Prader-Willi syndrome</article-title>
<source/>Am J Med Genet A
          <year>2013</year>
<volume>161A</volume>
<fpage>2052</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="pmid">23824702</pub-id>
</element-citation>
</ref>
<ref id="ref48">
<label>48</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vendrame</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Maski</surname>
<given-names>KP</given-names>
</name>
<name>
<surname>Chatterjee</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Heshmati</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Krishnamoorthy</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>WH</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Epilepsy in Prader-Willi syndrome: Clinical characteristics and correlation to genotype</article-title>
<source/>Epilepsy Behav
          <year>2010</year>
<volume>19</volume>
<fpage>306</fpage>
<lpage>10</lpage>
<pub-id pub-id-type="pmid">20727826</pub-id>
</element-citation>
</ref>
<ref id="ref49">
<label>49</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fan</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Greenwood</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Fisher</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pendyal</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Powell</surname>
<given-names>CM</given-names>
</name>
</person-group>
<article-title>Characteristics and frequency of seizure disorder in 56 patients with Prader-Willi syndrome</article-title>
<source/>Am J Med Genet A
          <year>2009</year>
<volume>149A</volume>
<fpage>1581</fpage>
<lpage>4</lpage>
<pub-id pub-id-type="pmid">19533781</pub-id>
</element-citation>
</ref>
<ref id="ref50">
<label>50</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Judson</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Wallace</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Sidorov</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Burette</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>B</given-names>
</name>
<name>
<surname>van Woerden</surname>
<given-names>GM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>GABAergic neuron-specific loss of ube3a causes Angelman syndrome-like EEG abnormalities and enhances seizure susceptibility</article-title>
<source/>Neuron
          <year>2016</year>
<volume>90</volume>
<fpage>56</fpage>
<lpage>69</lpage>
<pub-id pub-id-type="pmid">27021170</pub-id>
</element-citation>
</ref>
<ref id="ref51">
<label>51</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boyd</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Harden</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Patton</surname>
<given-names>MA</given-names>
</name>
</person-group>
<article-title>The EEG in early diagnosis of the Angelman (happy puppet) syndrome</article-title>
<source/>Eur J Pediatr
          <year>1988</year>
<volume>147</volume>
<fpage>508</fpage>
<lpage>13</lpage>
<pub-id pub-id-type="pmid">3409926</pub-id>
</element-citation>
</ref>
<ref id="ref52">
<label>52</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leyser</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Penna</surname>
<given-names>PS</given-names>
</name>
<name>
<surname>de Almeida</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Vasconcelos</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Nascimento</surname>
<given-names>OJ</given-names>
</name>
</person-group>
<article-title>Revisiting epilepsy and the electroencephalogram patterns in Angelman syndrome</article-title>
<source/>Neurol Sci
          <year>2014</year>
<volume>35</volume>
<fpage>701</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="pmid">24395242</pub-id>
</element-citation>
</ref>
<ref id="ref53">
<label>53</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Laan</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Renier</surname>
<given-names>WO</given-names>
</name>
<name>
<surname>Arts</surname>
<given-names>WF</given-names>
</name>
<name>
<surname>Buntinx</surname>
<given-names>IM</given-names>
</name>
<name>
<surname>vd Burgt</surname>
<given-names>IJ</given-names>
</name>
<name>
<surname>Stroink</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Evolution of epilepsy and EEG findings in Angelman syndrome</article-title>
<source/>Epilepsia
          <year>1997</year>
<volume>38</volume>
<fpage>195</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">9048672</pub-id>
</element-citation>
</ref>
<ref id="ref54">
<label>54</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yum</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>EH</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Ko</surname>
<given-names>TS</given-names>
</name>
<name>
<surname>Yoo</surname>
<given-names>HW</given-names>
</name>
</person-group>
<article-title>Implications of slow waves and shifting epileptiform discharges in Angelman syndrome</article-title>
<source/>Brain Dev
          <year>2013</year>
<volume>35</volume>
<fpage>245</fpage>
<lpage>51</lpage>
<pub-id pub-id-type="pmid">22704603</pub-id>
</element-citation>
</ref>
<ref id="ref55">
<label>55</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pelc</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Boyd</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Cheron</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Dan</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Epilepsy in Angelman syndrome</article-title>
<source/>Seizure
          <year>2008</year>
<volume>17</volume>
<fpage>211</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="pmid">17904873</pub-id>
</element-citation>
</ref>
<ref id="ref56">
<label>56</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Valente</surname>
<given-names>KD</given-names>
</name>
<name>
<surname>Andrade</surname>
<given-names>JQ</given-names>
</name>
<name>
<surname>Grossmann</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Kok</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Fridman</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Koiffmann</surname>
<given-names>CP</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Angelman syndrome: Difficulties in EEG pattern recognition and possible misinterpretations</article-title>
<source/>Epilepsia
          <year>2003</year>
<volume>44</volume>
<fpage>1051</fpage>
<lpage>63</lpage>
<pub-id pub-id-type="pmid">12887436</pub-id>
</element-citation>
</ref>
<ref id="ref57">
<label>57</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Franz</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Glauser</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Tudor</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Topiramate therapy of epilepsy associated with Angelman's syndrome</article-title>
<source/>Neurology
          <year>2000</year>
<volume>54</volume>
<fpage>1185</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">10720296</pub-id>
</element-citation>
</ref>
<ref id="ref58">
<label>58</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tan</surname>
<given-names>WH</given-names>
</name>
<name>
<surname>Bird</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Sadhwani</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Barbieri-Welge</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Skinner</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Horowitz</surname>
<given-names>LT</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A randomized controlled trial of levodopa in patients with Angelman syndrome</article-title>
<source/>Am J Med Genet A
          <year>2018</year>
<volume>176</volume>
<fpage>1099</fpage>
<lpage>107</lpage>
<pub-id pub-id-type="pmid">28944563</pub-id>
</element-citation>
</ref>
<ref id="ref59">
<label>59</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ruiz-Antoran</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Sancho-López</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cazorla-Calleja</surname>
<given-names>R</given-names>
</name>
<name>
<surname>López-Pájaro</surname>
<given-names>LF</given-names>
</name>
<name>
<surname>Leiva</surname>
<given-names>Á</given-names>
</name>
<name>
<surname>Iglesias-Escalera</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A randomized placebo controlled clinical trial to evaluate the efficacy and safety of minocycline in patients with Angelman syndrome (A-MANECE study)</article-title>
<source/>Orphanet J Rare Dis
          <year>2018</year>
<volume>13</volume>
<fpage>144</fpage>
<pub-id pub-id-type="pmid">30126448</pub-id>
</element-citation>
</ref>
<ref id="ref60">
<label>60</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meng</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ward</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Chun</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bennett</surname>
<given-names>CF</given-names>
</name>
<name>
<surname>Beaudet</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Rigo</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Towards a therapy for Angelman syndrome by targeting a long non-coding RNA</article-title>
<source/>Nature
          <year>2015</year>
<volume>518</volume>
<fpage>409</fpage>
<lpage>12</lpage>
<pub-id pub-id-type="pmid">25470045</pub-id>
</element-citation>
</ref>
<ref id="ref61">
<label>61</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>Allen</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Mabb</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>King</surname>
<given-names>IF</given-names>
</name>
<name>
<surname>Miriyala</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Taylor-Blake</surname>
<given-names>B</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons</article-title>
<source/>Nature
          <year>2011</year>
<volume>481</volume>
<fpage>185</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">22190039</pub-id>
</element-citation>
</ref>
<ref id="ref62">
<label>62</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salehi</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hsu</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Azen</surname>
<given-names>CG</given-names>
</name>
<name>
<surname>Mittelman</surname>
<given-names>SD</given-names>
</name>
<name>
<surname>Geffner</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Jeandron</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Effects of exenatide on weight and appetite in overweight adolescents and young adults with Prader-Willi syndrome</article-title>
<source/>Pediatr Obes
          <year>2017</year>
<volume>12</volume>
<fpage>221</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">27071367</pub-id>
</element-citation>
</ref>
<ref id="ref63">
<label>63</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McCandless</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Yanovski</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bird</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Salehi</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effects of MetAP2 inhibition on hyperphagia and body weight in Prader-Willi syndrome: A randomized, double-blind, placebo-controlled trial</article-title>
<source/>Diabetes Obes Metab
          <year>2017</year>
<volume>19</volume>
<fpage>1751</fpage>
<lpage>61</lpage>
<pub-id pub-id-type="pmid">28556449</pub-id>
</element-citation>
</ref>
<ref id="ref64">
<label>64</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schaller</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Watrin</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Sturny</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Massacrier</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Szepetowski</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Muscatelli</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>A single postnatal injection of oxytocin rescues the lethal feeding behaviour in mouse newborns deficient for the imprinted Magel2 gene</article-title>
<source/>Hum Mol Genet
          <year>2010</year>
<volume>19</volume>
<fpage>4895</fpage>
<lpage>905</lpage>
<pub-id pub-id-type="pmid">20876615</pub-id>
</element-citation>
</ref>
<ref id="ref65">
<label>65</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Swaab</surname>
<given-names>DF</given-names>
</name>
<name>
<surname>Purba</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Hofman</surname>
<given-names>MA</given-names>
</name>
</person-group>
<article-title>Alterations in the hypothalamic paraventricular nucleus and its oxytocin neurons (putative satiety cells) in Prader-Willi syndrome: A study of five cases</article-title>
<source/>J Clin Endocrinol Metab
          <year>1995</year>
<volume>80</volume>
<fpage>573</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">7852523</pub-id>
</element-citation>
</ref>
<ref id="ref66">
<label>66</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miller</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Tamura</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Butler</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Kimonis</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Sulsona</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Gold</surname>
<given-names>JA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Oxytocin treatment in children with Prader-Willi syndrome: A double-blind, placebo-controlled, crossover study</article-title>
<source/>Am J Med Genet A
          <year>2017</year>
<volume>173</volume>
<fpage>1243</fpage>
<lpage>50</lpage>
<pub-id pub-id-type="pmid">28371242</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>